Table 1 Characteristics of patients who received intrapleural streptokinase (IPSTK group, n = 12) and those who did not (Non IPSTK group, n = 19)

Age (years)

40 ± 15

41 ± 17

0.87

Sex (male/female)

9/3

16/3

0.53

Duration of symptoms (months)*

2.0 (0.2–12)

1.5 (0.1–36)

0.49

Chronic Empyema†

9 (75%)

11 (57.9%)

0.32

Hemoglobin (gm/dL)

10.1 ± 2.6

9.6 ± 2.0

0.63

TLC (/cmm)

11,100 ± 5489

14,494 ± 8271

0.19

ESR (1^st hr)

46 ± 19

57 ± 24

0.17

Blood Urea (mg/dL)

36 ± 15

41 ± 21

0.08

Serum creatinine (mg/dL)

1.2 ± 0.5

1.3 ± 0.8

0.64

Serum sodium (meq/L)

135.7 ± 4.1

134.9 ± 7.3

0.69

Serum potassium (meq/L)

4.3 ± 0.8

4.1 ± 0.4

0.38

Total bilirubin (mg/dL)

0.6 ± 0.3

0.8 ± 0.5

0.06

AST (IU/L)*

28 (17–218)

32 (12–381)

0.48

ALT (IU/L)*

19 (10–295)

33 (10–461)

0.54

SAP (IU/L)

203 ± 110

200 ± 105

0.95

Serum albumin (gm%)

2.9 ± 0.7

3.1 ± 0.7

0.54

Pl F total cells (/cmm)*

5000 (500–90,000)

2500 (800–160,000)

0.25

Pl F neutrophil count (/cmm)*

4500 (500–85,000)

2000 (100–150,000)

0.21

Pl F protein (gm/dL)

4.9 ± 1.1

4.4 ± 1.8

0.29

Pl F glucose (mg/dL)*

32 (0–80)

12 (3–70)

0.17

Presence of loss of lung volume

8 (66.7%)

12 (63.2%)

0.84

Tubercular empyema

6 (50%)

7 (36.8%)

0.47